Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Capital Expenditures (2016 - 2025)

Lineage Cell Therapeutics' Capital Expenditures history spans 16 years, with the latest figure at $399000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 27.98% year-over-year to $399000.0; the TTM value through Dec 2025 reached $522000.0, down 7.61%, while the annual FY2025 figure was $522000.0, 7.61% down from the prior year.
  • Capital Expenditures reached $399000.0 in Q4 2025 per LCTX's latest filing, up from $12000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $554000.0 in Q4 2024 to a low of -$401000.0 in Q4 2022.
  • Average Capital Expenditures over 5 years is $106450.0, with a median of $94000.0 recorded in 2022.
  • Peak YoY movement for Capital Expenditures: skyrocketed 2050.0% in 2021, then tumbled 374.66% in 2022.
  • A 5-year view of Capital Expenditures shows it stood at $146000.0 in 2021, then crashed by 374.66% to -$401000.0 in 2022, then surged by 122.69% to $91000.0 in 2023, then soared by 508.79% to $554000.0 in 2024, then fell by 27.98% to $399000.0 in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Capital Expenditures are $399000.0 (Q4 2025), $12000.0 (Q3 2025), and $14000.0 (Q2 2025).